Tweedy, Browne Co’s Vertex Pharmaceuticals VRTX Stock Holding History

Tweedy, Browne Co’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$18M	Buy	40,387 +1,239	+3%	+$578K	1.43%	17
2025 Q4	$17.7M	Buy	39,148 +83	+0.2%	+$35.8K	1.43%	19
2025 Q3	$15.3M	Buy	39,065 +1,812	+5%	+$757K	1.33%	18
2025 Q2	$16.6M	Sell	37,253 -1,063	-3%	-$490K	1.54%	17
2025 Q1	$18.6M	Sell	38,316 -2,315	-6%	-$1.08M	1.65%	16
2024 Q4	$16.4M	Sell	40,631 -12,969	-24%	-$6.01M	1.1%	20
2024 Q3	$24.9M	Sell	53,600 -746	-1%	-$358K	1.19%	18
2024 Q2	$25.5M	Sell	54,346 -12,353	-19%	-$5.36M	1.17%	18
2024 Q1	$27.9M	Sell	66,699 -65	-0.1%	-$27.5K	1.31%	16
2023 Q4	$27.2M	Sell	66,764 -8,240	-11%	-$3.04M	1.33%	16
2023 Q3	$26.1M	Buy	+75,004	New	+$26.2M	1.4%	14

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Tweedy, Browne Co's VRTX Position: Q1 2026 in Review

Tweedy, Browne Co increased its Vertex Pharmaceuticals (VRTX) stake by 3.2% in Q1 2026, buying an estimated $578K and bringing the position to 40,387 shares worth $18M. The position accounts for 1.43% of the portfolio, ranked #17.

Tweedy, Browne Co first reported a position in VRTX in Q3 2023 and has held it in 11 quarters since. The position peaked at $27.9M in Q1 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Tweedy, Browne Co held 40,387 shares of Vertex Pharmaceuticals worth $18M as of Q1 2026.
Tweedy, Browne Co bought 1,239 Vertex Pharmaceuticals shares in Q1 2026, an estimated $578K.
Vertex Pharmaceuticals made up 1.43% of Tweedy, Browne Co's portfolio in Q1 2026, its #17 holding.
Tweedy, Browne Co first reported a position in Vertex Pharmaceuticals in Q3 2023 and has held it in 11 quarters since.
Tweedy, Browne Co's Vertex Pharmaceuticals position peaked at $27.9M in Q1 2024.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Tweedy, Browne Co's 13F filing for Q1 2026, filed 6 May 2026.